Drug Discovery News
As in any industry, pharma and biotech are home to a lot of acronyms—many of them around new standards, techniques or technologies. For a while now, we’ve seen CRISPR snag a lot of headlines in the life sciences and in R&D for therapeutics, but that gene-editing technology has some competition from an acronym that has been around a lot longer: AI.
Of course, AI stands for artificial intelligence, and one of the reasons it hasn’t commanded more attention in academic labs or pharma R&D departments or in the news is that for decades, it has been largely theoretical. The idea of AI, the promise that it could hold—that was mostly what we had to work with.